Giovanni Barbara

List of Publications by Citations

126 papers	10,316 citations	47 h-index	101 g-index
153 ext. papers	12,164 ext. citations	6.5 avg, IF	5.82 L-index

#	Paper	IF	Citations
126	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology*, **2004**, 126, 693-702	13.3	1054
125	Intestinal permeability--a new target for disease prevention and therapy. *BMC Gastroenterology*, **2014**, 14, 189	3	810
124	Intestinal microbiota in functional bowel disorders: a Rome foundation report. *Gut*, **2013**, 62, 159-76	19.2	607
123	Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology*, **2007**, 132, 26-37	13.3	556
122	Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. *Gastroenterology*, **1996**, 110, 1036-42	13.3	539
121	Irritable bowel syndrome. *Nature Reviews Disease Primers*, **2016**, 2, 16014	51.1	429
120	Role for protease activity in visceral pain in irritable bowel syndrome. *Journal of Clinical Investigation*, **2007**, 117, 636-47	15.9	408
119	Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. *Gut*, **2009**, 58, 196-201	19.2	360
118	Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. *Gastroenterology*, **2009**, 137, 1425-34	13.3	262
117	Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. *American Journal of Gastroenterology*, **2009**, 104, 392-400	0.7	258
116	Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. *Alimentary Pharmacology and Therapeutics*, **2009**, 29 Suppl 1, 1-49	6.1	238
115	Interactions between commensal bacteria and gut sensorimotor function in health and disease. *American Journal of Gastroenterology*, **2005**, 100, 2560-8	0.7	217
114	A role for inflammation in irritable bowel syndrome?. *Gut*, **2002**, 51 Suppl 1, i41-4	19.2	188
113	Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. *Gastroenterology*, **1997**, 113, 1224-32	13.3	172
112	The Intestinal Microenvironment and Functional Gastrointestinal Disorders. *Gastroenterology*, **2016** ,	13.3	164
111	Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 11653-8	11.5	156
110	Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. *American Journal of Gastroenterology*, **2011**, 106, 1290-8	0.7	144

109	Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. *Clinical Gastroenterology and Hepatology*, **2005**, 3, 449-58	6.9	144
108	Functional gastrointestinal disorders and mast cells: implications for therapy. *Neurogastroenterology and Motility*, **2006**, 18, 6-17	4	140
107	New pathophysiological mechanisms in irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2004**, 20 Suppl 2, 1-9	6.1	135
106	The immune system in irritable bowel syndrome. *Journal of Neurogastroenterology and Motility*, **2011**, 17, 349-59	4.4	134
105	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. *Neurogastroenterology and Motility*, **2007**, 19, 440-52	4	125
104	Italian consensus conference for colonic diverticulosis and diverticular disease. *United European Gastroenterology Journal*, **2014**, 2, 413-42	5.3	112
103	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. *Gut*, **2017**, 66, 1252-1261	19.2	104
102	Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 245-52	6.1	103
101	Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. *Gastroenterology*, **2015**, 148, 1002-1011.e4	13.3	94
100	Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. *Gastroenterology*, **2014**, 146, 1659-1668	13.3	93
99	Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. *Current Gastroenterology Reports*, **2011**, 13, 308-15	5	86
98	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. *Gastroenterology*, **2015**, 149, 433-44.e7	13.3	85
97	Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. *Gastroenterology*, **2019**, 156, 46-58.e7	13.3	80
96	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut*, **2018**, 67, 263-270	19.2	79
95	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. *Gut*, **2015**, 64, 1774-82	19.2	78
94	Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. *Gastroenterology*, **2001**, 120, 1729-36	13.3	78
93	Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers. *FEMS Microbiology Ecology*, **2016**, 92,	4.3	75
92	Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. *Neurogastroenterology and Motility*, **2018**, 30, e13192	4	73

91	Randomised controlled trial of mesalazine in IBS. *Gut*, **2016**, 65, 82-90	19.2	67
90	Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. *Gastroenterology*, **2014**, 147, 69-77	13.3	61
89	Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. *Journal of Clinical Gastroenterology*, **2012**, 46 Suppl, S52-5	3	60
88	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 909-922	6.1	58
87	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. *United European Gastroenterology Journal*, **2017**, 5, 773-788	5.3	57
86	Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. *Diseases of the Colon and Rectum*, **2011**, 54, 1326-38	3.1	54
85	Effect of CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. *United European Gastroenterology Journal*, **2018**, 6, 604-613	5.3	53
84	Pre- and probiotic overview. *Current Opinion in Pharmacology*, **2018**, 43, 87-92	5.1	53
83	Postinfectious irritable bowel syndrome. *Journal of Pediatric Gastroenterology and Nutrition*, **2009**, 48 Suppl 2, S95-7	2.8	52
82	Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction. *Gastroenterology*, **2015**, 148, 771-782.e11	13.3	51
81	Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. *Neurogastroenterology and Motility*, **2012**, 24, 1118-e570	4	49
80	Novel therapeutic targets for enteric nervous system disorders. *Trends in Pharmacological Sciences*, **2007**, 28, 473-81	13.2	49
79	European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. *Colorectal Disease*, **2020**, 22 Suppl 2, 5-28	2.1	45
78	Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. *Neurogastroenterology and Motility*, **2014**, 26, 196-204	4	45
77	Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. *Alimentary Pharmacology and Therapeutics*, **2000**, 14, 1127-31	6.1	45
76	Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. *Neurogastroenterology and Motility*, **2012**, 24, 1134-e572	4	40
75	Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. *Transplantation Proceedings*, **2010**, 42, 15-8	1.1	40
74	Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. *Current Opinion in Gastroenterology*, **2014**, 30, 352-8	3	39

73	Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. *Neurogastroenterology and Motility*, **2011**, 23, 1084-91	4	39
72	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1673-1676	6.9	37
71	Stress, inflammation and the irritable bowel syndrome. *Canadian Journal of Gastroenterology & Hepatology*, **1999**, 13 Suppl A, 47A-49A		37
70	Unsuccessful octreotide treatment of the watermelon stomach. *Journal of Clinical Gastroenterology* , **1998**, 26, 345-6	3	36
69	Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. *Environmental Microbiology*, **2018**, 20, 3201-3213	5.2	35
68	Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. *European Journal of Clinical Investigation*, **2013**, 43, 1147-55	4.6	33
67	Interferon- s increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. *American Journal of Physiology - Renal Physiology*, **2016**, 310, G439-47	5.1	32
66	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. *Gastroenterology*, **2018**, 155, 168-179	13.3	31
65	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. *Gut*, **2009**, 58, 1571-5	19.2	28
64	Mucosal Barrier Defects in Irritable Bowel Syndrome. Who Left the Door Open?. *American Journal of Gastroenterology*, **2006**, 101, 1295-1298	0.7	26
63	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. *Gut*, **2020**, 69, 1966-1974	19.2	25
62	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756284818771305	4.7	25
61	Recent advances in understanding non-celiac gluten sensitivity. *F1000Research*, **2018**, 7,	3.6	24
60	Is gastroparesis a gastric disease?. *Neurogastroenterology and Motility*, **2019**, 31, e13562	4	23
59	Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). *Digestive and Liver Disease*, **2017**, 49, 595-603	3.3	22
58	Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons. *Pain*, **2018**, 159, 1257-1267	8	22
57	Managing the Inevitable Surge of Post-COVID-19 Functional Gastrointestinal Disorders. *American Journal of Gastroenterology*, **2021**, 116, 4-7	0.7	22
56	Probiotics in irritable bowel syndrome: Where are we?. *Neurogastroenterology and Motility*, **2018**, 30, e13513	4	22

55	Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. *Journal of Clinical Gastroenterology*, **2008**, 42 Suppl 3 Pt 2, S214-7	3	21
54	Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey. *United European Gastroenterology Journal*, **2018**, 6, 1245-1253	5.3	21
53	Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. *Digestive Diseases*, **2009**, 27 Suppl 1, 115-21	3.2	20
52	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. *United European Gastroenterology Journal*, **2021**, 9, 307-331	5.3	20
51	5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D. *Science Signaling*, **2018**, 11,	8.8	20
50	Evidence that tachykinins are the main NANC excitatory neurotransmitters in the guinea-pig common bile duct. *British Journal of Pharmacology*, **1998**, 124, 1703-11	8.6	19
49	Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues. *Digestive Diseases*, **2007**, 25, 245-8	3.2	18
48	Clinical approach to diarrhea. *Internal and Emergency Medicine*, **2012**, 7 Suppl 3, S255-62	3.7	17
47	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. *Expert Review of Molecular Diagnostics*, **2010**, 10, 389-93	3.8	17
46	East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. *Gut*, **2004**, 53, 1068-9	19.2	17
45	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. *Frontiers in Nutrition*, **2021**, 8, 718356	6.2	17
44	Gut microbiota and related diseases: clinical features. *Internal and Emergency Medicine*, **2010**, 5 Suppl 1, S57-63	3.7	16
43	Probiotics: could they turn out to be ineffective in irritable bowel syndrome?. *Digestive and Liver Disease*, **2000**, 32, 302-4	3.3	16
42	Implications of SARS-CoV-2 infection for neurogastroenterology. *Neurogastroenterology and Motility*, **2021**, 33, e14104	4	16
41	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. *Journal of Pediatrics*, **2018**, 195, 128-133.e1	3.6	15
40	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. *Digestive and Liver Disease*, **2018**, 50, 741-749	3.3	15
39	μ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. *Neurogastroenterology and Motility*, **2019**, 31, e13688	4	15
38	Treatment of Diverticular Disease With Aminosalicylates: The Evidence. *Journal of Clinical Gastroenterology*, **2016**, 50 Suppl 1, S60-3	3	12

37	IBS: biomarkers for IBS: ready for prime time?. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 9-10	24.2	11
36	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. *Nutrients*, **2020**, 12,	6.7	11
35	Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. *Neurogastroenterology and Motility*, **2018**, 30, e13388	4	11
34	Curriculum for neurogastroenterology and motility training: A report from the joint ANMS-ESNM task force. *Neurogastroenterology and Motility*, **2018**, 30, e13341	4	10
33	Glioplasticity in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2018**, 30, e13232	4	10
32	Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. *Neurogastroenterology and Motility*, **2017**, 29, e12928	4	10
31	Serine proteases: new players in diarrhoea-predominant irritable bowel syndrome. *Gut*, **2008**, 57, 1035-7	19.2	10
30	Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry. *United European Gastroenterology Journal*, **2018**, 6, 926-934	5.3	9
29	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. *Expert Review of Gastroenterology and Hepatology*, **2008**, 2, 735-40	4.2	8
28	An international survey on clinicians' perspectives on the diagnosis and management of chronic intestinal pseudo-obstruction and enteric dysmotility. *Neurogastroenterology and Motility*, **2020**, 32, e13937	4	8
27	Faecal microbial transplantation in IBS: ready for prime time?. *Gut*, **2020**, 69, 795-796	19.2	7
26	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 57-66	1.4	7
25	Nerve fiber overgrowth in patients with symptomatic diverticular disease. *Neurogastroenterology and Motility*, **2019**, 31, e13575	4	6
24	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. *Neurogastroenterology and Motility*, **2020**, 32, e13930	4	5
23	A New Reliable Method for Evaluating Gallbladder Dynamics: The 3-Dimensional Sonographic Examination. *Journal of Ultrasound in Medicine*, **2016**, 35, 297-304	2.9	5
22	Funding for gastrointestinal disease research in the European Union. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 593-595	18.8	5
21	What is the effect of inflammation on intestinal function?. *Inflammatory Bowel Diseases*, **2008**, 14 Suppl 2, S140-4	4.5	5
20	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. *Expert Opinion on Investigational Drugs*, **2018**, 27, 251-263	5.9	4

19	Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry. *United European Gastroenterology Journal*, **2019**, 7, 815-824	5.3	4
18	475j Nerve Growth and Plasticity in the Colonic Mucosa of Patients With Irritable Bowel Syndrome. *Gastroenterology*, **2010**, 138, S-65-S-65	13.3	4
17	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. *American Journal of Gastroenterology*, **2021**, 117,	0.7	4
16	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. *Neurogastroenterology and Motility*, **2021**, 33, e14238	4	4
15	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. *Digestive and Liver Disease*, **2021**, 53, 202-209	3.3	3
14	Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double-blind study. *GastroHep*, **2020**, 2, 295-308	1	2
13	Diagnostic challenges of symptomatic uncomplicated diverticular disease. *Minerva Gastroenterology*, **2017**, 63, 119-129	3	2
12	Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms. *Scientific Reports*, **2021**, 11, 8077	4.9	2
11	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. *Canadian Journal of Gastroenterology and Hepatology*, **2021**, 2021, 2534975	2.8	2
10	Role of inflammation in pediatric irritable bowel syndrome.. *Neurogastroenterology and Motility*, **2022**, e14365	4	2
9	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 23-29	1.4	1
8	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 39-44	1.4	0
7	Course of the Diverticular Disease: What is changing?. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 11-16	1.4	0
6	The Brain-Gut Axis and the Gender **2019**, 245-253		
5	In memoriam of a master of neurogastroenterology: Marcello Tonini (1944–2010). *Neurogastroenterology and Motility*, **2010**, 22, 942-943	4	
4	New perspectives in irritable bowel syndrome: introduction to part 2. *Digestive and Liver Disease*, **2009**, 41, 843	3.3	
3	Role of Smooth Muscle in Intestinal Inflammation. *Canadian Journal of Gastroenterology & Hepatology*, **1996**, 10, 249-253		
2	Protease-Activated Receptor 1 is implicated in irritable bowel syndrome mediators-induced signalling to human sensory neurons. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, OR3-3	0	

List of Publications

1 SeHCAT test for bile acid malabsorption: may the old become the gold one in the diagnostic burden of chronic diarrhea?. *Clinical and Translational Imaging*, **2021**, 9, 177-180 2